LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Lexicon Pharmaceuticals Inc

Closed

SectorHealthcare

1.12 3.7

Overview

Share price change

24h

Current

Min

1.06

Max

1.14

Key metrics

By Trading Economics

Income

29M

3.3M

Sales

28M

29M

Profit margin

11.266

Employees

103

EBITDA

31M

5.7M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+154.63% upside

Dividends

By Dow Jones

Next Earnings

11 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-7M

400M

Previous open

-2.58

Previous close

1.12

News Sentiment

By Acuity

50%

50%

173 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Lexicon Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

1 Nov 2024, 12:42 UTC

Major Market Movers

Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote

Peer Comparison

Price change

Lexicon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

154.63% upside

12 Months Forecast

Average 2.75 USD  154.63%

High 6 USD

Low 0.85 USD

Based on 5 Wall Street analysts offering 12 month price targets forLexicon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

0.6863 / 0.72Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

173 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
help-icon Live chat